Review article · 2025 · Open access

Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy

Xiaoqiang Kang, Yue Zhao, Hong Ling, Xiao Huang

Antibody Therapeutics, 9(1), 58–69 · Published 20 December 2025 · DOI 10.1093/abt/tbaf026

Open PDFView at the publisherCite this paper

In brief

“Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy” is a 2025 review article by Xiaoqiang Kang and 3 co-authors, published in Antibody Therapeutics. OpenAlex counts 11 citations as of 18 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Antibody Therapeutics.

Citations
11
Most cited in
2026 (11)
Field-weighted impact
0.73
References
96
Authors
4

Abstract

T-cell engagers (TCEs) represent an emerging class of immunotherapies that harness T cells' cytotoxic power to eliminate diseased cells-a transformative future therapeutic strategy. TCEs form immunological synapses to trigger potent immune responses, with proven efficacy in blood cancers; research expands their use to solid tumors via innovative molecular design and improved safety profiles. Beyond oncology, TCEs hold promise in autoimmune disorders by eliminating autoreactive cells, offering novel avenues for diseases like lupus. However, achieving optimal outcomes without disrupting immune homeostasis remains a challenge. Key obstacles-on-target off-tumor toxicity, cytokine release syndrome, tumor antigen loss, and T cell exhaustion-limit broader adoption. Current research addresses these via enhanced specificity, optimized design, improved druggability, and synergistic combinations. This review analyzes TCEs' mechanisms, challenges, innovations and applications, highlights our pipeline advances, and advocates sustained innovation to broaden TCE use across diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kang, X., Zhao, Y., Ling, H., & Huang, X. (2025). Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. Antibody Therapeutics, 9(1), 58–69. https://doi.org/10.1093/abt/tbaf026

MLA 9

Kang, Xiaoqiang, et al. “Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.” Antibody Therapeutics, vol. 9, no. 1, 2025, pp. 58–69. https://doi.org/10.1093/abt/tbaf026.

Chicago

Kang, Xiaoqiang, Yue Zhao, Hong Ling, and Xiao Huang. 2025. “Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.” Antibody Therapeutics 9 (1): 58–69. https://doi.org/10.1093/abt/tbaf026.

Harvard

Kang, X. et al. (2025) ‘Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy’, Antibody Therapeutics, 9(1), pp. 58–69. doi:10.1093/abt/tbaf026.

IEEE

X. Kang, Y. Zhao, H. Ling, and X. Huang, “Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy,” Antibody Therapeutics, vol. 9, no. 1, pp. 58–69, 2025, doi: 10.1093/abt/tbaf026.

BibTeX

@article{kang2025bispecific,
  title     = {{Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy}},
  author    = {Kang, Xiaoqiang and Zhao, Yue and Ling, Hong and Huang, Xiao},
  journal   = {Antibody Therapeutics},
  year      = {2025},
  volume    = {9},
  number    = {1},
  pages     = {58--69},
  doi       = {10.1093/abt/tbaf026},
  url       = {https://doi.org/10.1093/abt/tbaf026}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research

  • T-cell engagers
  • bispecific T-cell engagers
  • solid tumors
  • hematologic malignancies
  • autoimmune disease
  • lupus
  • on-target off-tumor toxicity
  • cytokine release syndrome

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Kang, X., Zhao, Y., Ling, H., & Huang, X. (2025). Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. Antibody Therapeutics, 9(1), 58–69. https://doi.org/10.1093/abt/tbaf026

How many times has this paper been cited?

11 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Antibody Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Xiaoqiang Kang, Yue Zhao, Hong Ling, Xiao Huang.

What is the DOI of this paper?

10.1093/abt/tbaf026, permanently at https://doi.org/10.1093/abt/tbaf026. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.